Skip to content

Erasca, Inc. ERAS Preferred Stock

Preferred Stock at other companies

Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$0
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$0
Exelixis logo
ExelixisEXEL
$0
Incyte logo
IncyteINCY
$0
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$0
Corcept Therapeutics logo
Corcept TherapeuticsCORT
$0

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Erasca, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Erasca, Inc.'s preferred stock?
Erasca, Inc. (ERAS) reported preferred stock of $0 in Q4 2025.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.